ArticleClinical immunology (Orlando, Fla.)2016
MicroRNA-21 deficiency protects from lupus-like autoimmunity in the chronic graft-versus-host disease model of systemic lupus erythematosus.
Article in Clinical immunology (Orlando, Fla.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Therapeutic Applications of Poly-miRNAs and miRNA Sponges.International journal of molecular sciences · 2025Review
- Role of miRNAs in Apoptosis Pathways of Immune Cells in Systemic Lupus Erythematosus.Immunity, inflammation and disease · 2025Review
- miRNA-21, an Important Regulator of Autoimmune Diseases.Current molecular medicine · 2025Review
- Lupus Nephritis from Pathogenesis to New Therapies: An Update.International journal of molecular sciences · 2024Review
- Chronic graft-versus-host disease detected by tissue-specific cell-free DNA methylation biomarkers.The Journal of clinical investigation · 2024Article
- miRNA-Mediated Control of B Cell Responses in Immunity and SLE.Frontiers in immunology · 2021Review
- MicroRNA-21 Regulates Diametrically Opposed Biological Functions of Regulatory T Cells.Frontiers in immunology · 2021Article
- miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome.Frontiers in pharmacology · 2020Review
- Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease.Frontiers in immunology · 2020Review
- Non-Coding RNAs in CD4Frontiers in immunology · 2020Review
- MicroRNAs in Autoimmunity and Hematological Malignancies.International journal of molecular sciences · 2018Review
- The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.Expert review of clinical immunology · 2018Review
- Tregs in SLE: an Update.Current rheumatology reports · 2018Review
- Regulatory T cells in renal disease.Clinical & translational immunology · 2018Review
- Relationship of peripheral blood mononuclear cells miRNA expression and parasitic load in canine visceral leishmaniasis.PloS one · 2018Article
- MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles.Oncogene · 2017Article
- Defective germinal center B-cell response and reduced arthritic pathology in microRNA-29a-deficient mice.Cellular and molecular life sciences : CMLS · 2017Article
- Estrogen-regulated STAT1 activation promotes TLR8 expression to facilitate signaling via microRNA-21 in systemic lupus erythematosus.Clinical immunology (Orlando, Fla.) · 2017Article
- Micro-RNA 10a Is Increased in Feline T Regulatory Cells and Increases Foxp3 Protein Expression Following In Vitro Transfection.Veterinary sciences · 2017Article
- miR-21 alters circulating Treg function in vascular disease-hope for restoring immunoregulatory responses in atherosclerosis?Annals of translational medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression primarily at the post-transcriptional level. Emerging evidence supports a regulatory role for miRNAs in the immune response and autoimmunity. In this work, we investigated the implication of miR-21 in the experimentally inducible bm12→B6 cGVHD model of systemic lupus erythematosus (SLE). cGVHD host mice deficient in miR-21 show a 2-fold reduction in splenomegaly, significantly reduced autoantibody titers and down-regulated components of the CD40:CD40L and CD28:CD80/86 co-stimulation pathways. Furthermore, we demonstrate that miR-21-deficient hosts have reduced CD4(+) IL-17(+) cell populations and an expanded CD4(+) CD25(+) FoxP3(+) cell compartment. We propose that miR-21 has a pluripotent role, serving to link distinct lymphocyte signaling pathways and acting as a "rheostat" for signals that promote B and T cell activation in lupus. Collectively, our experiments demonstrate that miR-21 deficiency in cGVHD host mice is sufficient to protect from lupus-like autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.